ArticlePaediatric drugs2018
The Effect of Alginate in Gastroesophageal Reflux in Infants.
Article in Paediatric drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Guidelines on diagnosis and management of gastroesophageal reflux disease in infants, children and adolescents: a joint consensus from Italian pediatric societies (SIP and SIGENP) -Part II: management.Italian journal of pediatrics · 2026Guideline
- Effectiveness of dietary interventions in managing pediatric gastroesophageal reflux disease: a comprehensive systematic review.European journal of medical research · 2025Pooled it
- Pharmacological treatment of gastro-oesophageal reflux in children.The Cochrane database of systematic reviews · 2023Pooled it
- Zinc-L-Carnosine (Polaprezinc) in managing infant regurgitation: a two-center randomized controlled trial.Frontiers in pediatrics · 2026Trial
- Magnesium Alginate in Gastro-Esophageal Reflux: A Randomized Multicenter Cross-Over Study in Infants.International journal of environmental research and public health · 2019Trial
- Reducing the use of proton pump inhibitors in infants with gastroesophageal reflux symptoms.Canadian family physician Medecin de famille canadien · 2025Article
- Prescriptions of anti-reflux drugs in neonatology and neonatal intensive care units: A large multicentre observational study (2014-2022).British journal of clinical pharmacology · 2024Observational
- Study on Nocturnal Infant Crying Evaluation (NICE) and Reflux Disease (RED).Children (Basel, Switzerland) · 2024Article
- Gastroesophageal reflux disease in children: What's new right now?World journal of gastrointestinal endoscopy · 2023Review
- Pediatric Laryngopharyngeal Reflux in the Last Decade: What Is New and Where to Next?Journal of clinical medicine · 2023Review
- Symptom Scores and pH-Impedance: Secondary Analysis of a Randomized Controlled Trial in Infants Treated for Gastroesophageal Reflux.Gastro hep advances · 2022Article
- Cow's Milk Allergy or Gastroesophageal Reflux Disease-Can We Solve the Dilemma in Infants?Nutrients · 2021Review
- Prescription of acid inhibitors in infants: an addiction hard to break.European journal of pediatrics · 2020Article
- Article
- Management of gastroesophageal reflux disease in pediatric patients with cerebral palsy.Canadian family physician Medecin de famille canadien · 2019Article
- Alginates: From the ocean to gastroesophageal reflux disease treatment.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2019Article
- Functional Gastrointestinal Disorders in Infancy: Impact on the Health of the Infant and Family.Pediatric gastroenterology, hepatology & nutrition · 2019Review
- Diagnosis and Management of Gastroesophageal Reflux Disease in Infants and Children: from Guidelines to Clinical Practice.Pediatric gastroenterology, hepatology & nutrition · 2019Review
- Gastroesophageal reflux in children: an updated review.Drugs in context · 2019Review
- Optimizing the Use of Medications and Other Therapies in Infant Gastroesophageal Reflux.Paediatric drugs · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGuidelines are contradictory regarding the use of alginate in infants with persisting gastroesophageal reflux (GER). While The British National Institute for Health and Care (NICE) guidelines consider alginate as a treatment option, the guidelines of the European and North-American Societies for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN, NASPGHAN) do not recommend alginates.
aimsWe assessed the efficacy of alginate to reduce GER episodes in infants.
methodsIn a prospective, observational study, we consecutively enrolled all infants referred for pH-multiple intraluminal impedance (pH-MII) recording because of persisting GER symptoms not responsive to behavior and dietetic modifications. A 48-h pH-MII was performed in all infants; a baseline recording was performed during the first 24 h while magnesium or sodium alginate was administered during the second 24 h. The primary endpoint was the difference in the total number of GER episodes per 24 h between the baseline day and the second day during which the alginate was administered. The secondary outcome was the difference in symptoms between each period. We also compared other pH-MII data from before and during alginate administration.
resultsWe recruited 43 infants (median age 68 days, range 25-306); three pH-MII tracings were excluded because of artifacts. The median number of all MII reflux episodes was significantly reduced during alginate administration (76.0 vs 69.5; p < 0.001). Crying-fussiness, cough and regurgitation episodes all significantly improved during alginate administration (p = 0.00012; p = 0.005 and p = 0.04, respectively). The following MII parameters also decreased during the alginate administration: acid (19.0 vs 14.5; p < 0.04), non-acid (52.0 vs 49.5; p < 0.004), proximal GER episodes (46.0 vs 41.4; p < 0.007), and bolus exposure index (1.9 vs 1.6; p = 0.002). At least three out of seven pH-MII parameters decreased by > 10% during the alginate period in 31/40 infants (77.5%), without a significant difference between magnesium and sodium alginate.
conclusionThese results suggest that alginate significantly decreases the number and extension of both acid and non-acid reflux episodes and associated symptoms in infants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.